Brief: Supernus Announces Promising Data From Open-Label Phase 2A Study Of Spn-820 In Adults With Major Depressive Disorder
17/10/2024 21:07
Oct 17 (Reuters) - Supernus Pharmaceuticals Inc
SUPN.O :
* SUPERNUS ANNOUNCES PROMISING DATA FROM OPEN-LABEL PHASE 2A
STUDY
OF SPN-820 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
* SUPERNUS PHARMACEUTICALS INC - PHASE 2A STUDY SHOWS RAPID
DECREASE IN DEPRESSIVE SYMPTOMS
* SUPERNUS PHARMACEUTICALS INC - SPN-820 WELL-TOLERATED WITH
FEW
ADVERSE EVENTS
* SUPERNUS PHARMACEUTICALS INC - TOPLINE RESULTS FROM PHASE
2B
STUDY EXPECTED FIRST-HALF 2025
Source text for Eikon: ID:nGNX8qZNnk
Further company coverage: SUPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing